Literature DB >> 25634009

Prognostic impact of preoperative tumor marker levels and lymphovascular invasion in pathological stage I adenocarcinoma and squamous cell carcinoma of the lung.

Tomonari Kinoshita1, Takashi Ohtsuka, Masaya Yotsukura, Keisuke Asakura, Taichiro Goto, Ikuo Kamiyama, Sotaro Otake, Atsushi Tajima, Katsura Emoto, Yuichiro Hayashi, Mitsutomo Kohno.   

Abstract

INTRODUCTION: Some unfavorable prognostic factors for stage I non-small-cell lung cancers have been reported; however, they are not reflected in the current Tumor-Node-Metastasis classification.
METHODS: We retrospectively reviewed 629 patients who underwent complete resection of pathological stage I adenocarcinomas (ADs) or squamous cell carcinomas (SQs) at two institutes between 1996 and 2011. The correlation between clinicopathological characteristics and survival rates was analyzed to identify prognostic factors.
RESULTS: Multivariate analysis indicated that among ADs, high serum carcinoembryonic antigen levels (p = 0.04 for overall survival [OS]; p < 0.01 for recurrence-free survival [RFS]; p = 0.02 for disease-specific survival [DSS]), lymphatic permeation (p < 0.01 for RFS and DSS), and vascular invasion (p < 0.01 for OS and RFS; p = 0.03 for DSS) were independent prognostic factors. Among SQs, high squamous cell carcinoma antigen (SCC) (p < 0.05 for OS), and vascular invasion (p < 0.05 for RFS and DSS) were independently prognostic. We suggest that among completely resected tumors less than or equal to 5 cm without lymph node metastasis, the current stages IA and IB AD with high serum carcinoembryonic antigen levels, lymphatic permeation, or vascular invasion should be upgraded to stage IB and IIA, respectively. The current stage IA SQ with high SCC antigen levels or vascular invasion should be upgraded to stage IB. These reclassifications accurately reflect survival status (p < 0.04 in all comparisons).
CONCLUSIONS: Some important differences in prognostic factors were observed between AD and SQ. High preoperative serum tumor marker levels and lymphovascular invasion should be included as additional criteria in the forthcoming Tumor-Node-Metastasis staging.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25634009     DOI: 10.1097/JTO.0000000000000480

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  11 in total

1.  Choice of the surgical approach for patients with stage I lung squamous cell carcinoma ≤3 cm.

Authors:  Chunji Chen; Yiyang Wang; Xufeng Pan; Shijie Fu; Yubo Shi; Jun Yang; Rui Wang
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

2.  Ideal prognostic model in lung squamous cell carcinoma.

Authors:  Tomonari Kinoshita
Journal:  Transl Lung Cancer Res       Date:  2020-06

3.  How long is cessation of preoperative smoking required to improve postoperative survival of patients with pathological stage I non-small cell lung cancer?

Authors:  Toshiyuki Shima; Tomonari Kinoshita; Mao Uematsu; Naomichi Sasaki; Yusuke Sugita; Reiko Shimizu; Masahiko Harada; Tsunekazu Hishima; Hirotoshi Horio
Journal:  Transl Lung Cancer Res       Date:  2020-10

4.  Unique intravascular tumor microenvironment predicting recurrence of lung squamous cell carcinoma.

Authors:  Kakeru Hisakane; Koichi Saruwatari; Satoshi Fujii; Keisuke Kirita; Shigeki Umemura; Shingo Matsumoto; Kiyotaka Yoh; Seiji Niho; Hironobu Ohmatsu; Takeshi Kuwata; Atsushi Ochiai; Akihiko Gemma; Masahiro Tsuboi; Koichi Goto; Genichiro Ishii
Journal:  J Cancer Res Clin Oncol       Date:  2015-10-31       Impact factor: 4.553

5.  Restrictive ventilatory impairment is associated with poor outcome in patients with cT1aN0M0 peripheral squamous cell carcinoma of the lung.

Authors:  Hiroyuki Tao; Junichi Soh; Hiromasa Yamamoto; Toshiya Fujiwara; Tsuyoshi Ueno; Makio Hayama; Mikio Okazaki; Ryujiro Sugimoto; Motohiro Yamashita; Yoshifumi Sano; Kazunori Okabe; Motoki Matsuura; Kazuhiko Kataoka; Shigeharu Moriyama; Shinichi Toyooka; Shinichiro Miyoshi
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

6.  Distribution of circulating tumor DNA in lung cancer: analysis of the primary lung and bone marrow along with the pulmonary venous and peripheral blood.

Authors:  Taichiro Goto; Yosuke Hirotsu; Kenji Amemiya; Takahiro Nakagomi; Daichi Shikata; Yujiro Yokoyama; Kenichiro Okimoto; Toshio Oyama; Hitoshi Mochizuki; Masao Omata
Journal:  Oncotarget       Date:  2017-07-25

7.  Using Natural Language Processing and Machine Learning to Preoperatively Predict Lymph Node Metastasis for Non-Small Cell Lung Cancer With Electronic Medical Records: Development and Validation Study.

Authors:  Danqing Hu; Shaolei Li; Huanyao Zhang; Nan Wu; Xudong Lu
Journal:  JMIR Med Inform       Date:  2022-04-25

8.  Surgical resection for clinical stage I high-grade neuroendocrine carcinoma of the lung.

Authors:  Eisuke Mochizuki; Shun Matsuura; Kyohei Oishi; Koichi Miyashita; Koshiro Ichijyo; Syunya Furukawa; Miyuki Nagaoka; Shinichiro Mikura; Masaru Tsukui; Naoki Koshimizu; Shogo Sakurai; Kazuhiro Asada; Toshihiro Shirai
Journal:  World J Surg Oncol       Date:  2018-02-17       Impact factor: 2.754

9.  Prognostic significance of peripheral CD8+CD28+ and CD8+CD28- T cells in advanced non-small cell lung cancer patients treated with chemo(radio)therapy.

Authors:  Chao Liu; Wang Jing; Ning An; Aijie Li; Weiwei Yan; Hui Zhu; Jinming Yu
Journal:  J Transl Med       Date:  2019-10-17       Impact factor: 5.531

10.  Assessment of Clinicopathological Characteristics and Development of an Individualized Prognostic Model for Patients With Hepatoid Adenocarcinoma of the Stomach.

Authors:  Jian-Xian Lin; Zu-Kai Wang; Qing-Qi Hong; Peng Zhang; Zi-Zhen Zhang; Liang He; Quan Wang; Liang Shang; Lin-Jun Wang; Ya-Feng Sun; Zhi-Xiong Li; Jun-Jie Liu; Fang-Hui Ding; En-De Lin; Yong-An Fu; Shuang-Ming Lin; Jian-Wei Xie; Ping Li; Chao-Hui Zheng; Chang-Ming Huang
Journal:  JAMA Netw Open       Date:  2021-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.